Successful Utilization of the GLP-1 Receptor Agonist Semaglutide in Treating the Manifestations of Recalcitrant Celiac Disease. acbr. 2025;9(5):392-395. Accessed September 20, 2026. https://www.fortunejournals.org/ojs/index.php/acbr/article/view/15136